Top 10 Heal Care Stocks To Buy Right Now

Top 10 Heal Care Stocks To Buy Right Now: ACADIA Pharmaceuticals Inc.(ACAD)

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on drug discovery and clinical development of novel treatments for central nervous system disorders. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase III clinical development as a treatment for Parkinson's disease psychosis. It is also developing AGN-XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development in collaboration with Meiji Seika Kaisha, Ltd. In addition, ACADIA Pharmaceuticals Inc. is developing two preclinical programs in the area of Parkinson?s disease. The product candidates in the company?s pipeline emanate from discoveries made using its proprietary drug discovery platform. The company was founded in 1993 and is headquartered in San Diego, California.

Advisors' Opinion:

• [By Cheryl Swanson]

  Alzheimer's drugs in developmental stages
  I'm not making any predictions, but those willing to do plenty of homework may find some interesting plays among the smaller caps in the Alzheimer's space. A small-cap that's getting lots of attention is Acadia Pharmaceuticals (NASDAQ: ACAD  ) . Acadia's drug Pimavanserin may someday prove useful for psychosis in Alzheimer's patients, as discussed in a Motley Fool article by Todd Campbell. More recently, George Budwell pointed out heavy short interest as the drug gets closer to regulatory filing for its experimental treatment--which has a more direct application to Parkinson's. Acadia also has drugs in development for glaucoma and chronic pain.

• [By Sean Williams]

  ACADIA Pharmaceuticals (NASDAQ: ACAD  ) added on 63% since last Friday, following an announcement that the FDA will allow it to file an accelerated new drug applicat! ion for its Parkinson's disease anti-psychosis drug, Pimavanserin. ACADIA's drug met the primary endpoint of demonstrating highly significant anti-psychotic activity and the secondary endpoint of increased motoric tolerability in its late-stage trial, which provided more than enough evidence for the FDA to give the company the go-ahead to skip another confirmatory trial. Pimavanserin's chances for approval definitely got a boost, but ACADIA's valuation certainly is giving me cause for concern.

• [By Keith Speights]

  3. Acadia Pharmaceuticals (NASDAQ: ACAD  )
  There aren't any known deals in the works for Acadia, but it wouldn't be surprising if acquisition stories emerge in the not-too-distant future. Several factors could contribute to the small biotech ending up as a target for a larger player.

• [By Rich Duprey]

  Shortcut to approval
  It was FDA action that also caused ACADIA Pharmaceuticals (NASDAQ: ACAD  ) to rocket 64% higher and become the best performing stock on the market. It was allowed to bypass a second late-stage trial for its Parkinson's disease psychosis treatment pimavanserin. As the Fool's Brian Orelli notes, while ACADIA still has to perform tests for drug-drug interaction and chemistry and manufacturing -- so it won't be submitting its new drug application before next year -- the elimination of the confirmatory trial speeds up the time to market dramatically.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-10-heal-care-stocks-to-buy-right-now.html